Format

Send to

Choose Destination
Am J Ophthalmol. 2007 Mar;143(3):538-9. Epub 2006 Nov 13.

Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.

Author information

1
University of South Florida College of Medicine, Tampa, Florida 33612, USA. cemargo@mindspring.com

Abstract

PURPOSE:

To determine the feasibility of a case-control study of phosphodiesterase (PDE)-5 inhibitors and nonarteritic ischemic optic neuropathy (NION).

DESIGN:

Retrospective cohort study using the National Veterans Health Administration's pharmacy and clinical databases.

METHODS:

setting: National database. patient population: Male veterans 50 years of age and older with newly diagnosed NION or "possible" NION. interventional procedure: Dispensed prescription for a PDE-5 inhibitor. outcome measure: Incidence of NION and "possible" NION based on exposure to PDE-5 inhibitors.

RESULTS:

The relative risk of NION among men prescribed a PDE-5 inhibitor was 1.02 (95% confidence interval [CI]: 0.92 to 1.12). The relative risk of possible NION among men prescribed a PDE-5 inhibitor was 1.34 (95% CI: 1.17 to 1.55).

CONCLUSIONS:

The collective risk of NION and possible NION was marginally significant (relative risk [RR] 1.10 95% CI: 1.02 to 1.20). A case-control study, in which the dependent variable is NION and the effect size of the PDE-5 inhibitor is assumed small, is feasible.

PMID:
17317413
DOI:
10.1016/j.ajo.2006.10.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center